A new COVID-19 medication has been approved in Abu Dhabi for the treatment of mild to moderate cases and those who have had direct contact with a patient.
The emirate's Department of Health (DoH) has partnered with Swiss healthcare company Roche to provide casirivimab and imdevimab to certain categories of patients.
The antibody combination has already been approved in the European Union and Japan, and conditionally approved in the UK and Australia.
It is also authorised for emergency use in the United States, India, Switzerland and Canada, and is recommended by the World Health Organisation (WHO).
.@DoHSocial has partnered with Swiss healthcare company @Roche to provide a new Covid-19 medication, approved for emergency use, to treat mild to moderate Covid-19 cases and those who have had direct contact with a positive case.
— مكتب أبوظبي الإعلامي (@ADMediaOffice) December 1, 2021
Read more: https://t.co/vGQXyUvhGB pic.twitter.com/Yj9JxVgemP
H.H. Sheikh Hamdan approves strategy for Dubai Longevity Authority
Saif bin Zayed meets justice, interior ministers on crime congress sidelines
UAE highlights efforts to advance international judicial cooperation
Sheikh Abdullah holds bilateral talks with global counterparts at UN
Three UAE aid convoys enter Gaza carrying 458 tonnes of supplies
H.H. Sheikh Sultan earns Exeter PhD in Management
RTA launches smart testing facility at Dubai Silicon Oasis
'Abu Dhabi Declaration' adopted as UN crime congress opens
